Press Release: Evolus to Report Third Quarter Financial Results on November 4, 2026

Dow Jones10-21
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--October 21, 2026--

Evolus, Inc. $(EOLS)$, a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the U.S. financial markets close.

Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.

To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.

Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13762943. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics by building a differentiated portfolio of injectable brands that address the evolving needs of practitioners and patients. Our portfolio includes Jeuveau(R) (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, Evolysse(R) , a collection of unique injectable hyaluronic acid (HA) gels, and Profhilo(R) , the market-leading injectable for skin quality in Europe, which Evolus has exclusively licensed for development and commercialization in the United States. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau(R) , Nuceiva(R) , and Evolysse(R) are registered trademarks of Evolus, Inc.

Profhilo(R) is a registered trademark of IBSA Institut Biochimique SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261021297995/en/ 

 
    CONTACT:    Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: ir@evolus.com

Media:

Email: media@evolus.com

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment